Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Eisai terminates E-4177 development

Aug. 9, 1996

Renin inhibitors described by Ciba-Geigy

Aug. 9, 1996

KRH-594: Wakunaga's angiotensin II antagonist

Aug. 9, 1996

Angiotensin II antagonists disclosed by Tanabe Seiyaku

Aug. 9, 1996

Alpha2-adrenoceptor agonists effective as cardiac arrest treatment

July 26, 1996

SR-140333 claimed as a cardioregulatory drug

July 26, 1996

BES and BENSPM claimed as vascular proliferative disorders treatment

July 26, 1996

Glaxo Wellcome claims GR-79236 for reducing myocardial injury

July 26, 1996

Pierre Fabre reports antioxidants

July 26, 1996

Hoechst Marion Roussel synthesizes TNF-alpha production inhibitor

July 19, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...